Hawthorn's OPCs (oligomeric procyanidins) and vitexin-2''-O-rhamnoside work through: (1) PDE3 inhibition in cardiac myocytes — increases cAMP → stronger cardiac contraction (positive inotropy) without proarrhythmic risk; (2) eNOS activation — increases coronary and peripheral NO → vasodilation; (3) ACE inhibition (mild) — reduces angiotensin II → decreases afterload; (4) antiarrhythmic — extends the refractory period of cardiac action potentials, reducing premature beats; (5) antioxidant — protects cardiac tissue from ischemia-reperfusion injury via ROS scavenging. The PDE3 mechanism is pharmacologically similar to milrinone (prescription heart failure drug) but much milder.
Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.